BioNTech (NASDAQ:BNTX) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research note released on Monday,Benzinga reports. HC Wainwright currently has a $150.00 price target on the stock.

Several other analysts also recently weighed in on the stock. Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $93.00 to $145.00 in a research report on Tuesday, September 24th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, September 19th. Canaccord Genuity Group restated a “buy” rating and set a $171.00 price target on shares of BioNTech in a research report on Thursday, November 14th. HSBC lifted their price objective on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Finally, Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 2nd. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and a consensus target price of $137.54.

BioNTech Stock Performance

Shares of BNTX stock opened at $101.87 on Monday. The company’s fifty day simple moving average is $113.57 and its 200-day simple moving average is $97.36. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company has a market cap of $24.42 billion, a PE ratio of -48.51 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business’s revenue was up 38.9% on a year-over-year basis. During the same period last year, the business earned $0.73 EPS. As a group, equities research analysts anticipate that BioNTech will post -3.68 EPS for the current year.

Hedge Funds Weigh In On BioNTech

A number of institutional investors have recently added to or reduced their stakes in BNTX. Janney Montgomery Scott LLC acquired a new position in shares of BioNTech in the first quarter valued at $314,000. ProShare Advisors LLC boosted its position in shares of BioNTech by 10.4% in the first quarter. ProShare Advisors LLC now owns 6,785 shares of the company’s stock valued at $626,000 after acquiring an additional 637 shares during the period. Covestor Ltd boosted its position in shares of BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after acquiring an additional 133 shares during the period. CANADA LIFE ASSURANCE Co boosted its position in shares of BioNTech by 79.6% in the first quarter. CANADA LIFE ASSURANCE Co now owns 3,426 shares of the company’s stock valued at $316,000 after acquiring an additional 1,518 shares during the period. Finally, Crewe Advisors LLC bought a new stake in shares of BioNTech in the first quarter valued at about $75,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.